User menu

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.

Bibliographic reference Foster, Graham R ; Coppola, Carmine ; Derbala, Moutaz ; Ferenci, Peter ; Orlandini, Alessandra ; et. al. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.. In: PLoS One, Vol. 11, no.3, p. e0151703 (2016)
Permanent URL http://hdl.handle.net/2078.1/180115
  1. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available: http://www.hcvguidelines.org. Accessed 24 Aug 2014.
  2. Hoofnagle Jay H., Sherker Averell H., Therapy for Hepatitis C — The Costs of Success, 10.1056/nejme1401508
  3. Muir Andrew J, The Rapid Evolution of Treatment Strategies for Hepatitis C, 10.1038/ajg.2014.66
  4. The Lancet, Only just the beginning of the end of hepatitis C, 10.1016/s0140-6736(14)60087-8
  5. Jayasekera Channa R., Barry Michele, Roberts Lewis R., Nguyen Mindie H., Treating Hepatitis C in Lower-Income Countries, 10.1056/nejmp1400160
  6. Ghany Marc G., Strader Doris B., Thomas David L., Seeff Leonard B., Diagnosis, management, and treatment of hepatitis C: An update, 10.1002/hep.22759
  7. McHutchison John G., Manns Michael, Patel Keyur, Poynard Thierry, Lindsay Karen L., Trepo Christian, Dienstag Jules, Lee William M., Mak Carmen, Garaud Jean–Jacques, Albrecht Janice K., Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C, 10.1053/gast.2002.35950
  8. Reddy K. Rajender, Shiffman Mitchell L., Morgan Timothy R., Zeuzem Stefan, Hadziyannis Stephanos, Hamzeh Fayez M., Wright Teresa L., Fried Michael, Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment, 10.1016/j.cgh.2006.10.008
  9. Sievert William, Dore Gregory J., McCaughan Geoffrey W., Yoshihara Motoko, Crawford Darrell H., Cheng Wendy, Weltman Martin, Rawlinson William, Rizkalla Bishoy, DePamphilis Jean K., Roberts Stuart K., , Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1, 10.1002/hep.24180
  10. Epstein Mark, Guidelines for good pharmacoepidemiology practices (GPP), 10.1002/pds.1082
  11. Ferenci Peter, Aires Rodrigo, Ancuta Ioan, Arohnson Andrew, Cheinquer Hugo, Delic Dragan, Gschwantler Michael, Larrey Dominique, Tallarico Ludovico, Schmitz Manuela, Tatsch Fernando, Ouzan Denis, A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin, 10.1111/liv.12439
  12. Singal Ashwani K., Jampana Sarat C., Anand Bhupinderjit S., Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naïve Patients with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled Trials, 10.1007/s10620-011-1765-0
  13. Ge Dongliang, Fellay Jacques, Thompson Alexander J., Simon Jason S., Shianna Kevin V., Urban Thomas J., Heinzen Erin L., Qiu Ping, Bertelsen Arthur H., Muir Andrew J., Sulkowski Mark, McHutchison John G., Goldstein David B., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, 10.1038/nature08309
  14. Manns Michael P, McHutchison John G, Gordon Stuart C, Rustgi Vinod K, Shiffman Mitchell, Reindollar Robert, Goodman Zachary D, Koury Kenneth, Ling Mei-Hsiu, Albrecht Janice K, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, 10.1016/s0140-6736(01)06102-5
  15. Fried Michael W., Shiffman Mitchell L., Reddy K. Rajender, Smith Coleman, Marinos George, Gonçales Fernando L., Häussinger Dieter, Diago Moises, Carosi Giampiero, Dhumeaux Daniel, Craxi Antonio, Lin Amy, Hoffman Joseph, Yu Jian, Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection, 10.1056/nejmoa020047
  16. Hadziyannis Stephanos J., Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C : A Randomized Study of Treatment Duration and Ribavirin Dose, 10.7326/0003-4819-140-5-200403020-00010
  17. Aronsohn A., Ancuta I., Caruntu F., Coppola C., Delic D., Digiacomo A., Dusheiko G. M., Lengyel G., Marcellin P., Orlandini A., Pruthi J., Silva G. F., Tallarico L., Schmitz M., Tatsch F., Korner E., Cheinquer H., Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort, 10.1111/jvh.12179
  18. Negro F., Clément S., Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C, 10.1111/j.1365-2893.2009.01186.x
  19. Reddy K. Rajender, Shiffman Mitchell L., Rodriguez–Torres Maribel, Cheinquer Hugo, Abdurakhmanov Djamal, Bakulin Igor, Morozov Viacheslav, Silva Giovanni Faria, Geyvandova Natalia, Stanciu Carol, Rabbia Michael, McKenna Michael, Thommes James A., Harrison Stephen A., Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads, 10.1053/j.gastro.2010.08.051
  20. McHutchison John G., Lawitz Eric J., Shiffman Mitchell L., Muir Andrew J., Galler Greg W., McCone Jonathan, Nyberg Lisa M., Lee William M., Ghalib Reem H., Schiff Eugene R., Galati Joseph S., Bacon Bruce R., Davis Mitchell N., Mukhopadhyay Pabak, Koury Kenneth, Noviello Stephanie, Pedicone Lisa D., Brass Clifford A., Albrecht Janice K., Sulkowski Mark S., Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection, 10.1056/nejmoa0808010
  21. Sulkowski Mark S., Shiffman Mitchell L., Afdhal Nezam H., Reddy K. Rajender, McCone Jonathan, Lee William M., Herrine Steven K., Harrison Stephen A., Poordad F. Fred, Koury Kenneth, Deng Weiping, Noviello Stephanie, Pedicone Lisa D., Brass Clifford A., Albrecht Janice K., McHutchison John G., Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate, 10.1053/j.gastro.2010.07.059
  22. Lindsay Karen L., Morishima Chihiro, Wright Elizabeth C., Dienstag Jules L., Shiffman Mitchell L., Everson Gregory T., Lok Anna S.F., Bonkovsky Herbert L., Lee William M., Morgan Timothy R., Ghany Marc G., Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Re-treatment of Chronic Hepatitis C, 10.1016/j.cgh.2007.11.020